Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Completed · Phase 2
Conditions studied: Intraocular Melanoma, Melanoma (Skin)
In brief
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to determine the effectiveness of vaccine therapy given with interleukin-12 in treating patients who have stage III or stage IV melanoma.
Key facts
- Study ID
- NCT00003339
- Run by
- University of Southern California
- People needed
- 48
- Starts
- 1998-11-01
- Expected to finish
- 2004-09-01
- Last updated by the study team
- 2014-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beckman Research Institute, City of Hope — Duarte, California, United States
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.